DK3104838T3 - Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf - Google Patents
Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf Download PDFInfo
- Publication number
- DK3104838T3 DK3104838T3 DK15707019.4T DK15707019T DK3104838T3 DK 3104838 T3 DK3104838 T3 DK 3104838T3 DK 15707019 T DK15707019 T DK 15707019T DK 3104838 T3 DK3104838 T3 DK 3104838T3
- Authority
- DK
- Denmark
- Prior art keywords
- therapeutic
- preparation
- methods
- nanoparticles
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461939363P | 2014-02-13 | 2014-02-13 | |
| PCT/US2015/015887 WO2015123562A1 (en) | 2014-02-13 | 2015-02-13 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3104838T3 true DK3104838T3 (da) | 2020-02-24 |
Family
ID=52595474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15707019.4T DK3104838T3 (da) | 2014-02-13 | 2015-02-13 | Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10080723B2 (enExample) |
| EP (1) | EP3104838B1 (enExample) |
| JP (1) | JP6573895B2 (enExample) |
| CA (1) | CA2939261C (enExample) |
| DK (1) | DK3104838T3 (enExample) |
| ES (1) | ES2770733T3 (enExample) |
| HU (1) | HUE047934T2 (enExample) |
| PL (1) | PL3104838T3 (enExample) |
| PT (1) | PT3104838T (enExample) |
| SI (1) | SI3104838T1 (enExample) |
| WO (1) | WO2015123562A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3104838T (pt) | 2014-02-13 | 2020-02-14 | Pfizer | Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos de fazer e utilizar as mesmas |
| EP4299058A3 (en) | 2014-06-24 | 2024-03-27 | The Trustees of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
| US20170049709A1 (en) | 2015-08-21 | 2017-02-23 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| JP2019509299A (ja) * | 2016-03-22 | 2019-04-04 | ファイザー・インク | 治療用ナノ粒子を調製する方法 |
| CA3060306A1 (en) | 2017-05-09 | 2018-11-15 | Dignity Health | Drug delivery composition and method of fabrication |
| WO2019055539A1 (en) | 2017-09-12 | 2019-03-21 | Prudhomme Robert K | CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME |
| US12357582B2 (en) | 2017-11-03 | 2025-07-15 | The Trustees Of Princeton University | Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations |
| EP3784705A4 (en) * | 2018-04-23 | 2022-03-02 | Graybug Vision, Inc. | IMPROVED CONTINUOUS PRODUCTION OF MICROPARTICLES |
| CN120305263A (zh) | 2018-06-15 | 2025-07-15 | 汉达癌症医药责任有限公司 | 卡博替尼的盐类于制备治疗癌症的剂型的用途 |
| WO2020018890A1 (en) | 2018-07-19 | 2020-01-23 | Prudhomme Robert K | Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents |
| US11731099B2 (en) | 2018-07-20 | 2023-08-22 | The Trustees Of Princeton University | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation |
| WO2024108094A1 (en) * | 2022-11-18 | 2024-05-23 | Haima Therapeutics, Llc | Lyophilization buffers for peptide-decorated liposomes |
| AU2024215796A1 (en) | 2023-01-31 | 2025-05-15 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6869884B2 (en) * | 2002-08-22 | 2005-03-22 | Chartered Semiconductor Manufacturing Ltd. | Process to reduce substrate effects by forming channels under inductor devices and around analog blocks |
| AU2004259209A1 (en) * | 2003-07-23 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| EA020954B1 (ru) | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| AU2013315125B2 (en) | 2012-09-17 | 2018-07-26 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| EP2895156B1 (en) | 2012-09-17 | 2019-05-08 | Pfizer Inc. | Process for preparing therapeutic nanoparticles |
| PE20160930A1 (es) * | 2013-09-16 | 2016-09-03 | Astrazeneca Ab | Nanoparticulas polimericas terapeuticas y metodos para su elaboracion y uso. |
| PT3104838T (pt) | 2014-02-13 | 2020-02-14 | Pfizer | Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos de fazer e utilizar as mesmas |
| ES2834927T3 (es) * | 2014-03-14 | 2021-06-21 | Pfizer | Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas |
-
2015
- 2015-02-13 PT PT157070194T patent/PT3104838T/pt unknown
- 2015-02-13 US US15/118,737 patent/US10080723B2/en active Active
- 2015-02-13 PL PL15707019T patent/PL3104838T3/pl unknown
- 2015-02-13 WO PCT/US2015/015887 patent/WO2015123562A1/en not_active Ceased
- 2015-02-13 EP EP15707019.4A patent/EP3104838B1/en active Active
- 2015-02-13 CA CA2939261A patent/CA2939261C/en active Active
- 2015-02-13 SI SI201531085T patent/SI3104838T1/sl unknown
- 2015-02-13 DK DK15707019.4T patent/DK3104838T3/da active
- 2015-02-13 HU HUE15707019A patent/HUE047934T2/hu unknown
- 2015-02-13 ES ES15707019T patent/ES2770733T3/es active Active
- 2015-02-13 JP JP2016551767A patent/JP6573895B2/ja active Active
-
2018
- 2018-09-07 US US16/124,605 patent/US10583092B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6573895B2 (ja) | 2019-09-11 |
| US20190111004A1 (en) | 2019-04-18 |
| US10583092B2 (en) | 2020-03-10 |
| ES2770733T3 (es) | 2020-07-02 |
| JP2017505800A (ja) | 2017-02-23 |
| EP3104838B1 (en) | 2020-01-01 |
| HUE047934T2 (hu) | 2020-05-28 |
| WO2015123562A1 (en) | 2015-08-20 |
| US20170042828A1 (en) | 2017-02-16 |
| US10080723B2 (en) | 2018-09-25 |
| CA2939261A1 (en) | 2015-08-20 |
| SI3104838T1 (sl) | 2020-04-30 |
| PT3104838T (pt) | 2020-02-14 |
| PL3104838T3 (pl) | 2020-07-13 |
| EP3104838A1 (en) | 2016-12-21 |
| CA2939261C (en) | 2023-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3511019T3 (da) | Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf | |
| IL258931A (en) | Therapeutic compounds and methods | |
| DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
| IL250685A0 (en) | Medicinal substance induces cytotoxicity | |
| IL252532A0 (en) | Polycyclic carbamoylpyridone compounds and their pharmaceutical use | |
| DK3212255T3 (da) | Selvorienterende sprøjte og sprøjtegrænseflade | |
| IL247777B (en) | Ablation catheter and ablation apparatus | |
| IL249370A0 (en) | Fap-enabled medical substances and related uses | |
| DK3209308T3 (da) | Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf | |
| GB201403093D0 (en) | Therapeutic compounds and their use | |
| SG10201500986TA (en) | Catheter devices and related methods | |
| HUE040395T2 (hu) | Ápolóeszköz és eljárás | |
| DK3117777T3 (da) | Spredningstomografifremgangsmåde og spredningstomografianordning | |
| GB201404470D0 (en) | Therapeutic methods and materials | |
| HUE047934T2 (hu) | Terápiás szert tartalmazó terápiás nanorészecskék, ezek elõállítása és alkalmazása | |
| IL283335B (en) | Dihydropyrimidine-2-one compounds and their medical use | |
| IL247325A0 (en) | Therapeutic methods using noribogaine and related compounds | |
| DK3114118T3 (da) | p-SUBSTITUEREDE ASYMMETRISKE URINSTOFFER OG MEDICINSK ANVENDELSE DERAF | |
| PL3129398T3 (pl) | Nowe środki medyczne i ich zastosowanie | |
| GB201418809D0 (en) | Therapeutic agents and uses thereof | |
| DK3094338T3 (da) | Test og lægemiddel | |
| IL251930B (en) | Benzylhydroxy derivatives, their preparation and medical uses | |
| GB201416899D0 (en) | Medical devices and related methods | |
| GB201410387D0 (en) | Compounds and their therapeutic use | |
| GB201403496D0 (en) | Compounds and their therapeutic use |